Nkarta, Inc. (NKTX) Stock

Nkarta, Inc. (NKTX) is a Healthcare stock trading at $2.83 (as of 2026-06-18), with a market capitalization of $232.52M and a trailing P/E of -2.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer. It engineers natural killer cells with receptors to target specific antigens on tumor cells, including NKX101 in Phase I for relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes and NKX019 for B-cell malignancies targeting CD19, with a collaboration involving CRISPR Therapeutics AG.

Valuation — source: SEC EDGAR (first-party)
Price	$2.83
Market Cap	$232.52M
P/E Ratio	-2.4
EV / EBITDA	-1.9
Price / Book	0.81
DCF Value (model)	$-20.88
DCF Upside vs Price	-836.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$0.00
Return on Equity	-35.0%
Current Ratio	12.96

Financial Health — source: SEC EDGAR
Altman Z-Score	-1.15 (distress)

Valuation vs Sector & Industry
Stock P/E	-2.4
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-111.5%
vs Industry	-114.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	RA CAPITAL MANAGEMENT, L.P. ($22.80M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Paul J. Hastings
Employees	157
Country	US
IPO Date	2020-07-10

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.